Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
Frontiers in Oncology
|
March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status
Marcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology
|
July 21, 2017
Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: Are we offering the best?
Victor Srougi, Jose de Bessa, Fabio Y Tanno, et al.
Clinical Endocrinology
|
June 26, 2025
Endocrine Implications of Thyroid Incidentalomas Detected During Lymphoma Staging With 18F-Fluorodeoxyglucose Positron Emission Tomography
Marcos Tadashi Kakitani Toyoshima, Roberta Morgado Ferreira Zuppani, Isabelle Pinheiro Amaro, et al.
The Lancet. Oncology
|
July 13, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Ming Gao, Young Joo Park, Chia-Chi Lin, et al.
Clinical Endocrinology
|
June 11, 2013
A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives
Priscila S Signorini, Maria Inez C França, Cleber P Camacho, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 2, 2025
Do Prognostic Differences Exist Among High-Risk <i>RET</i> Mutations? A Comparison of Outcomes Between the <i>RET</i> C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma
Jie Zhang, Luciana Audi Castroneves, Susan C Lindsey, et al.
Archives of Endocrinology and Metabolism
|
February 15, 2021
Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism
Jose Miguel Dora, Rosa Paula Mello Biscolla, Gustavo Caldas, et al.
The New England Journal of Medicine
|
February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
Martin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
Frontiers in Endocrinology
|
April 30, 2024
Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report
Isabelle P A Magalhaes, Bibiana D Boger, Nathalia L Gomes, et al.
The New England Journal of Medicine
|
October 23, 2023
Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer
Julien Hadoux, Rossella Elisei, Marcia S Brose, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
Frontiers in Oncology
|
March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status
Marcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology
|
July 21, 2017
Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: Are we offering the best?
Victor Srougi, Jose de Bessa, Fabio Y Tanno, et al.
Clinical Endocrinology
|
June 26, 2025
Endocrine Implications of Thyroid Incidentalomas Detected During Lymphoma Staging With 18F-Fluorodeoxyglucose Positron Emission Tomography
Marcos Tadashi Kakitani Toyoshima, Roberta Morgado Ferreira Zuppani, Isabelle Pinheiro Amaro, et al.
The Lancet. Oncology
|
July 13, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Ming Gao, Young Joo Park, Chia-Chi Lin, et al.
Clinical Endocrinology
|
June 11, 2013
A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives
Priscila S Signorini, Maria Inez C França, Cleber P Camacho, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 2, 2025
Do Prognostic Differences Exist Among High-Risk <i>RET</i> Mutations? A Comparison of Outcomes Between the <i>RET</i> C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma
Jie Zhang, Luciana Audi Castroneves, Susan C Lindsey, et al.
Archives of Endocrinology and Metabolism
|
February 15, 2021
Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism
Jose Miguel Dora, Rosa Paula Mello Biscolla, Gustavo Caldas, et al.
The New England Journal of Medicine
|
February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
Martin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
Frontiers in Endocrinology
|
April 30, 2024
Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report
Isabelle P A Magalhaes, Bibiana D Boger, Nathalia L Gomes, et al.
The New England Journal of Medicine
|
October 23, 2023
Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer
Julien Hadoux, Rossella Elisei, Marcia S Brose, et al.
Page
of 8